AMBEEPHA Ambee Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 725.9 as of 2026-11-12 14:00:00
Rank 115 of all scored
Data completeness 90%
Data completeness 90%
Score breakdown
Consistency 77
Profitability 66
Solvency 100
Valuation 0
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency EPS grew in 3 of 4 years
- Profitability Average ROE 23.57% (efficient: above 15%)
- Solvency Practically debt-free (loan risk cannot hurt it)
Concerns
- Consistency Net loss in 1 of the last 5 years
- Valuation P/E 315.61 is high (above 20)
- Valuation Trades at 49.28x book value (NAV Tk 14.73, price Tk 725.9)
- Valuation Price is 2582% above the Graham fair value (Tk 27.1)
Risk flags
- Small cap (< Tk 200 cr): most exposed to manipulation and volatility
- Thin trading (last day ~Tk 0.00 cr)
- Within 6.59% of its 52-week low: check WHY before treating it as cheap
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
6.6% above the low, 14.3% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 77.3%
- Institution 5.6%
- Public 17.2%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | -5.42 | 18.68 | -1 | — | — |
| 2022 | 3.36 | 21.96 | 1 | 10 | 0 |
| 2023 | 3.79 | 9.73 | 1 | 15 | 0 |
| 2024 | 4.03 | 12.26 | 1 | 10 | 0 |
| 2025 | 2.21 | 13.47 | 1 | 10 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 0%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.